Stereoselective synthesis of new conformationally restricted analogues of a potent CGRP receptor antagonist

Organic Letters

Volumn 7, Issue 12, 2005, Pages 2465-2468

  Zuev, Dmitry ^a   Michne, Jodi A ^a,b   Huang, Hong ^a   Beno, Brett R ^a   Wu, Dedong ^a   Gao, Qi ^a   Torrente, John R ^a   Xu, Cen ^a   Conway, Charles M ^a   Macor, John E ^a   Dubowchik, Gene M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE RECEPTOR; LACTAM DERIVATIVE; LIDOFLAZINE; PROTEIN INHIBITOR; PYRAZINE DERIVATIVE;

ARTICLE; DIASTEREOISOMER; DRUG CONFORMATION; DRUG POTENCY; DRUG SYNTHESIS; NITRATION; RACEMIZATION; STEREOCHEMISTRY; SUBSTITUTION REACTION;

BENZIMIDAZOLES; CRYSTALLOGRAPHY, X-RAY; LACTAMS; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PIPERAZINES; PIPERIDINES; PYRAZINES; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; STEREOISOMERISM;

EID: 20544457345     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol0510062     Document Type: Article

References (20)

1. Mann, A. In Practice of Medicinal Chemistry, 2nd ed.; Wermuth, C. G., Ed.; Academic Press: San Diego, 2003; Chapter 15, p 233.
2. Wermuth, C. G. In Practice of Medicinal Chemistry, 2nd ed.; Wermuth, C. G., Ed.; Academic Press: San Diego, 2003; Chapter 14, p 215.
3. 19,20
4. Edvinsson, L.; Sams, A.; Jansen-Olesen, I.; Tajti, J.; Kane, S. A.; Rutledge, R. Z.; Koblan, K. S.; Hill, R. G.; Longmore, J. Eur. J. Phamacol. 2001, 415, 39.
5. For a detailed description of the molecular modeling procedure, see Supporting Information.
6. Van den Branden, S.; Compernolle, F.; Hoornaert, G. J. Chem. Soc., Perkin Trans. 1 1992, 1035.
7. Saleh, M. A.; Compernolle, F.; Van den Branden, S.; De Buysser, W.; Hoornaert, G. J. Org. Chem. 1993, 58, 690.
8. Nate, H. et al. Chem. Pharm. Bull. 1987, 35, 2825.
9. Boukouvalas, J.; Lachance, N.; Ouellet, M.; Trudeau, M. Tetrahedron Lett. 1998, 39, 7665.
10. Trost, B. M.; Kunz, R. A. J. Org. Chem. 1974, 39, 2475.
11. Feuer H.; Panda, C. S.; Hou, L.; Bevinakatti, H. S. Synthesis 1983, 187.
12. 2O (10%)/TFA (0.1%); starting % B, 20; final % B, 80; gradient time, 20 min; end time, 25 min.
13. Full crystallographic data for 13b have been deposited to the Cambridge Crystallographic Data Center (CCDC reference number 238932).
14. Takeda, K.; Ogura, H. Synth. Commun. 1980, 10, 373.
15. McOmie, J. F. W.; Watts, M. L.; West, D. E. Tetrahedron 1968, 24, 2289.
16. For a detailed description of the CGRP binding assay, see Supporting Information.
17. Brain, S. D.; Cambridge, H. Gen. Pharmacol. 1996, 27, 607.
18. Edvinsson, L. CNS Drugs 2001, 15, 745.
19. Juaneda, C.; Dumont, Y.; Quirion, R. Trends Pharmacol. Sci. 2000, 21, 432.
20. McLatchie, L. M.; Fraser, N. J.; Main, M. J.; Wise, A.; Brown, J.; Thompson, N.; Solari, R.; Lee, M. G.; Foord, S. M. Nature 1998, 393, 333.